PRT062607
Cat. No.: DC7254
Chemical Structure
1370261-97-4
We are official vendor of:
More than 5000 active chemicals with high quality for research!
Field of application
PRT062607(P505-15) anti-SYK activity is at least 80-fold greater than its affinity For other kinases. at least 80-fold greater than its affinity For other kinases. PRT062607 potently inhibits B cell antigen receptor-mediated B cell signaling and activation (IC50 0.27 and 0.28 μM, respectively) and Fcε receptor 1-mediated basophil degranulation (IC50 0.15 μM). PRT062607 inhibits BCR-dependent secretion of the chemokines CCL3 and CCL4 by CLL cells, and leukemia cell migration toward the tissue homing chemokines CXCL12, CXCL13, and beneath stromal cells. PRT062607 furthermore inhibits Syk and extracellular signal-regulated kinase phosphorylation after BCR triggering. For the detailed information of PRT062607, the solubility of PRT062607 in water, the solubility of PRT062607 in DMSO, the solubility of PRT062607 in PBS buffer, the animal experiment (test) of PRT062607, the cell expriment (test) of PRT062607, the in vivo, in vitro and clinical trial test of PRT062607, the EC50, IC50,and Affinity of PRT062607, Please contact DC Chemicals..
Cas No.: |
1370261-97-4 |
Chemical Name: |
4-((3-(2H-1,2,3-triazol-2-yl)phenyl)amino)-2-(((1R,2S)-2-aminocyclohexyl)amino)pyrimidine-5-carboxamide hydrochloride |
Synonyms: |
PRT2607; PRT-2607; PRT 2607; PRT062607; PRT-062607; PRT 062607; BIIB057; BIIB-057; BIIB 057; P-505-15; P 505-15; P505-15; P-50515; P 50515; P50515 |
SMILES: |
NC(C1=CN=C(N[C@H]2[C@@H](N)CCCC2)N=C1NC3=CC=CC(N4N=CC=N4)=C3)=O.[H]Cl |
Formula: |
C19H24ClN9O |
M.Wt: |
429.913 |
Purity: |
>98% |
Sotrage: |
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: |
PRT062607(P505-15) anti-SYK activity is at least 80-fold greater than its affinity For other kinases. at least 80-fold greater than its affinity For other kinases. PRT062607 potently inhibits B cell antigen receptor-mediated B cell signaling and activation (IC50 0.27 and 0.28 μM, respectively) and Fcε receptor 1-mediated basophil degranulation (IC50 0.15 μM). PRT062607 inhibits BCR-dependent secretion of the chemokines CCL3 and CCL4 by CLL cells, and leukemia cell migration toward the tissue homing chemokines CXCL12, CXCL13, and beneath stromal cells. PRT062607 furthermore inhibits Syk and extracellular signal-regulated kinase phosphorylation after BCR triggering. For the detailed information of PRT062607, the solubility of PRT062607 in water, the solubility of PRT062607 in DMSO, the solubility of PRT062607 in PBS buffer, the animal experiment (test) of PRT062607, the cell expriment (test) of PRT062607, the in vivo, in vitro and clinical trial test of PRT062607, the EC50, IC50,and Affinity of PRT062607, Please contact DC Chemicals. |
MSDS
COA
LOT NO. |
DOWNLOAD |
|
|
2018-0101 |
|
Get Quote